Coya Therapeutics, Inc. (COYA)
(Delayed Data from NSDQ)
$6.06 USD
+0.24 (4.12%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $5.95 -0.11 (-1.82%) 6:42 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Income Statements
Fiscal Year end for Coya Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 6 | 0 | 0 | NA | NA |
Cost Of Goods | 0 | 0 | 0 | NA | NA |
Gross Profit | 6 | 0 | 0 | NA | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 14 | 10 | 5 | 0 | 0 |
Income After Depreciation & Amortization | -8 | -10 | -5 | 0 | 0 |
Non-Operating Income | 1 | -2 | 0 | NA | NA |
Interest Expense | 0 | 0 | 0 | NA | NA |
Pretax Income | -7 | -12 | -5 | NA | NA |
Income Taxes | 1 | 0 | 0 | NA | NA |
Minority Interest | 0 | 0 | 0 | NA | NA |
Investment Gains/Losses | 0 | 0 | 0 | NA | NA |
Other Income/Charges | 0 | 0 | 0 | NA | NA |
Income From Cont. Operations | -8 | -12 | -5 | NA | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | NA | NA |
Net Income (GAAP) | -8 | -12 | -5 | NA | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -8 | -10 | -5 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | NA | NA |
Income After Depreciation & Amortization | -8 | -10 | -5 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 10.16 | 2.59 | 2.59 | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.79 | -4.73 | -1.89 | NA | NA |
Diluted Net EPS (GAAP) | -0.79 | -4.73 | -1.89 | NA | NA |
Fiscal Year end for Coya Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 3.43 | 0.13 | 6.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 3.43 | 0.13 | 6.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 6.67 | 5.61 | 4.19 | 3.56 | 3.26 |
Income After SG&A, R&D, and Dept/Amort Expenses | -3.24 | -5.48 | 1.81 | -3.56 | -3.26 |
Non-Operating Income | 0.34 | 0.43 | 0.17 | 0.14 | 0.16 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -2.89 | -5.05 | 1.99 | -3.42 | -3.10 |
Income Taxes | 0.00 | 0.00 | 0.72 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -2.89 | -5.05 | 1.27 | -3.42 | -3.10 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -2.89 | -5.05 | 1.27 | -3.42 | -3.10 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 14.92 | 14.46 | 8.37 | 9.95 | 9.95 |
Diluted EPS Before Non-Recurring Items | -0.19 | -0.35 | 0.15 | -0.34 | -0.31 |
Diluted Net EPS (GAAP) | -0.19 | -0.35 | 0.14 | -0.34 | -0.31 |